RxDoctor Payments Data

Louis Cubba, MD

Internal Medicine · San Francisco, CANPI 1649201716

Payments from drug & device makers

$350,903in general payments, 2019–2025

Across 431 payments — averaging $814.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$198K
  • Gilead$151K
  • Shionogi Inc$975
  • Merck$324
  • Janssen Products, LP$99

What the payments were for

  • Consulting fees$44,43013%
  • Speaking & faculty fees$264,03675%
  • Travel & lodging$32,4959%
  • Food & beverage$9,8433%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company214$198,269
Gilead212$151,236
Shionogi Inc1$975
Merck3$324
Janssen Products, LP1$99

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$350,903 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$277,667
Medicare patients
368
Services billed
3,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala384$1,685,413
RukobiaFostemsavir Tromethamine48$438,463
DescovyEmtricitabine/Tenofov Alafenam153$341,839
DovatoDolutegravir Sodium/Lamivudine86$278,690
TivicayDolutegravir Sodium109$256,315
OdefseyEmtricitab/Rilpiviri/Tenof Ala67$253,236
TriumeqAbacavir/Dolutegravir/Lamivudi60$229,675
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf46$224,804
GenvoyaElviteg/Cob/Emtri/Tenof Alafen37$159,416
PrezcobixDarunavir/Cobicistat47$131,786
JulucaDolutegravir/Rilpivirine26$114,791
PifeltroDoravirine44$89,500
IngrezzaValbenazine Tosylate11$86,955
IsentressRaltegravir Potassium32$80,806
EliquisApixaban92$76,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$151,236$2,186,668574 claims
Viiv Healthcare CompanyRukobia, Dovato, Tivicay, Triumeq, Juluca$198,269$1,317,933329 claims
Janssen Products, LPSymtuza$99$224,80446 claims
MerckPifeltro, Isentress$324$170,30676 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →